Skip to main content

Table 1 Patient characteristics and survival analysis (by clinicopathological subtype)

From: Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer

Characteristic Luminal A (n = 119) Luminal B Ki67+ (n = 52) Luminal B HER2 + (22) HER2 overexpression (16) TNBC (46) Statistics P
Age (years) 51.67 ± 10.10 50.88 ± 8.16 55.41 ± 8.98 52.13 ± 6.49 51.91 ± 10.90 0.896 0.467
Menopause       2.378 0.667
Postmenopausal 56 24 14 7 22   
Premenopausal 63 28 8 9 24   
Family history       2.075 0.722
No 109 49 21 16 42   
Yes 10 3 1 0 4   
Diameter 2.15 ± 0.98 2.32 ± 0.94 2.43 ± 1.07 3.09 ± 1.49 2.50 ± 1.18 3.292 0.012
Quadrant       16.851 0.395
Areolar 3 1 0 0 1   
Inner upper 28 8 0 2 7   
Inner lower 14 5 1 2 3   
Outer lower 21 11 3 2 6   
Outer upper 53 27 18 10 29   
Enhancement patterns       59.901 0.000
Homogeneous 40(33.6%) 18(34.6%) 7(31.8%) 5(31.3%) 12(26.1%)   
Heterogeneous 71(59.7%) 29(55.8%) 8(36.4%) 3(18.8%) 10(21.7%)   
Peripherals 8(6.7%) 5(9.6%) 7(31.8%) 8(50.0%) 24(52.2%)   
Difference of MVD (Edge - Center) 3.12 ± 6.26 3.18 ± 7.95 7.61 ± 8.53 7.98 ± 8.97 10.23 ± 8.72 9.543 0.000
Grade of DMVD       42.300 0.000
Uniform distribution 102(85.7%) 44(84.6%) 14(63.6%) 6(37.5%) 21(45.7%)   
Uneven distribution 17(14.3%) 8(15.4%) 8(36.4%) 10(62.5%) 25(54.3%)   
Histological grade       30.927 0.000
I 37(31.1%) 16(30.8%) 0(0%) 1(6.3%) 9(19.6%)   
II 77(64.7%) 29(55.8%) 16(72.7%) 10(62.5%) 34(73.9%)   
III 5(4.2%) 7(13.5%) 6(27.3%) 5(31.3%) 3(6.5%)   
Cancer thrombosis       7.806 0.099
Negative 89 41 11 10 34   
Positive 30 11 11 6 12   
Nodal metastasis       6.825 0.145
Negative 60 24 8 3 23   
Positive 59 28 14 13 23   
Number of metastatic nodes 2.09 ± 4.16 2.94 ± 5.01 6.77 ± 9.63 11.88 ± 11.37 4.89 ± 9.70 9.167 0.000
Clinical stage       50.721 0.000
I 33(27.7%) 15(28.8%) 1(4.5%) 0(0%) 10(21.7%)   
IIA 38(31.9%) 11(21.2%) 10(45.5%) 4(25.0%) 13(28.3%)   
IIB 39(32.8%) 21(40.4%) 4(18.2%) 4(25.0%) 16(34.8%)   
IIIA 7(5.9%) 3(5.8%) 3(13.6%) 3(18.8%) 2(4.3%)   
IIIB 1(0.8%) 2(3.8%) 2(9.1%) 1(6.3%) 1(2.2%)   
IIIC 1(0.8%) 0(0%) 2(9.1%) 4(25%) 4(8.7%)   
IV 0(0%) 0(0%) 0(0%) 0(0%) 0(0%)   
P53 (%) 27.76 ± 30.19 32.65 ± 34.17 41.55 ± 30.32 30.19 ± 32.23 35.50 ± 35.33 1.141 0.338
Operation       5.455 0.244
Mastectomy 102 47 21 16 43   
Tumorectomy 17 5 1 0 3   
Chemotherapy program       49.253 0.002
Not performed 1(0.8%) 0(0%) 0(0%) 0(0%) 1(2.2%)   
CMF 2(1.7%) 0(0%) 0(0%) 0(0%) 0(0%)   
CAF or AC 42(35.3%) 17(32.7%) 2(9.1%) 0(0%) 11(23.9%)   
CEF or EC 21(17.6%) 12(23.1%) 10(45.5%) 5(31.3%) 14(30.4%)   
T or TC or TP 42(35.3%) 15(28.8%) 4(18.2%) 2(12.5%) 13(28.3%)   
TAC or A-T 10(8.4%) 8(15.4%) 6(27.3%) 9(56.3%) 7(15.2%)   
Radiotherapy       6.682 0.154
Not performed 67 27 10 4 27   
Performed 52 25 12 12 19   
Endocrine therapy       262.436 0.000
Not performed 0(0%) 0(0%) 0(0%) 16(100%) 46(100%)   
TAM 75(63.0%) 32(61.5%) 12(54.5%) 0(0%) 0(0%)   
LHRH 11(9.2%) 7(13.5%) 0(0%) 0(0%) 0(0%)   
AI 33(27.7%) 13(25.0%) 10(45.5%) 0(0%) 0(0%)   
Targeted therapy       33.619 0.000
Not performed 119(100%) 52(100%) 20(90.9%) 13(81.3%) 46(100%)   
Performed 0(0%) 0(0%) 2(9.1%) 3(18.8%) 0(0%)   
Overall survival 99.2% 98.1% 86.4% 87.5% 91.3% 17.629 0.024
Event 1 1 3 2 4   
Deaths 1 1 3 2 3   
Lost to follow-up 0 0 0 0 1   
Median survival time 54.0 48.0 36.0 29.4 35.2 31.845 0.000
Disease-free survival 98.3% 94.3% 72.7% 75.0% 82.6% 56.588 0.001
Event 2 3 6 4 7   
Local recurrence 0 1 0 0 0   
Contralateral breast cancer 1 1 2 0 0   
Lung metastasis 0 0 0 1 1   
Hepatic metastasis 0 0 2 1 2   
Brain metastasis 0 0 0 1 2   
Multi-organ 1 1 2 1 2   
Lost to Follow-up 0 0 0 0 1   
Disease-free survival 54.0 48.0 35.4 22.5 31.7 59.248 0.000
Follow-up time       4.741 0.001
Median 23.0 25.5 30.5 17.0 20.0   
Range 12-59 12-49 12-38 12-25 12-53   
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us